Ocugen (OCGN) News Today → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free OCGN Stock Alerts $1.91 -0.07 (-3.54%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 4:34 AM | americanbankingnews.comOcugen's (OCGN) "Buy" Rating Reaffirmed at HC WainwrightMay 19 at 3:32 AM | americanbankingnews.comChardan Capital Reiterates Buy Rating for Ocugen (NASDAQ:OCGN)May 18 at 5:46 AM | americanbankingnews.comOcugen, Inc. to Post FY2025 Earnings of ($0.27) Per Share, Chardan Capital Forecasts (NASDAQ:OCGN)May 17 at 5:41 PM | prnewswire.comROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGNMay 17 at 1:49 PM | stockhouse.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmMay 17 at 10:10 AM | marketbeat.comOcugen, Inc. (NASDAQ:OCGN) to Post FY2025 Earnings of ($0.27) Per Share, Chardan Capital ForecastsOcugen, Inc. (NASDAQ:OCGN - Free Report) - Research analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Ocugen in a research note issued to investors on Wednesday, May 15th. Chardan Capital analyst D. Gataulin anticipates that the company will earn ($0.27) per share for thMay 16 at 3:39 PM | marketbeat.comOcugen (NASDAQ:OCGN) Shares Gap Down to $1.96Ocugen (NASDAQ:OCGN) Shares Gap Down to $1.96May 16 at 12:19 AM | markets.businessinsider.comBuy Rating Affirmed for Ocugen on Strong Financials and Advancing Clinical PipelineMay 16 at 12:19 AM | markets.businessinsider.com4 Analysts Assess Ocugen: What You Need To KnowMay 16 at 12:19 AM | msn.comOcugen Advances with Phase 1/2 Trial for Stargardt Disease TreatmentMay 15, 2024 | msn.comOcugen Advances Gene Therapy Trials, Targets 2026 for Key Regulatory ApprovalsMay 15, 2024 | marketbeat.comOcugen (NASDAQ:OCGN) Announces Quarterly Earnings ResultsOcugen (NASDAQ:OCGN - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01. The business had revenue of $1.01 million during the quarter. During the same period in the previous year, the business earned ($0.07) earnings per share.May 15, 2024 | marketbeat.comChardan Capital Reaffirms "Buy" Rating for Ocugen (NASDAQ:OCGN)Chardan Capital restated a "buy" rating and set a $5.00 price objective on shares of Ocugen in a research report on Wednesday.May 15, 2024 | finance.yahoo.comOcugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...May 15, 2024 | globenewswire.comOcugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene TherapyMay 15, 2024 | prnewswire.comIMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmMay 14, 2024 | investorplace.comOCGN Stock Earnings: Ocugen Beats EPS for Q1 2024May 14, 2024 | globenewswire.comOcugen Provides Business Update with First Quarter 2024 Financial ResultsMay 12, 2024 | msn.comOcugen to Highlight Clinical Developments at Upcoming Life Sciences ConferencesMay 12, 2024 | americanbankingnews.comOcugen (OCGN) to Release Quarterly Earnings on TuesdayMay 10, 2024 | prnewswire.comROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGNMay 10, 2024 | globenewswire.comOcugen Announces Distribution of Series C Preferred Stock to Holders of its Common StockMay 10, 2024 | globenewswire.comOcugen to Present at May 2024 Investor ConferencesMay 8, 2024 | investorplace.comMillionaire Blueprint: 3 Stocks Under $5 With Massive Growth Potential by 2028May 7, 2024 | marketbeat.comOcugen (OCGN) to Release Earnings on TuesdayOcugen (NASDAQ:OCGN) will be releasing earnings before the market opens on Tuesday, May 14, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=594226)May 6, 2024 | stockhouse.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmMay 5, 2024 | markets.businessinsider.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OcugenMay 4, 2024 | msn.comOcugen to Unveil Q1 2024 Financials and Business Updates in Upcoming CallMay 3, 2024 | prnewswire.comROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGNMay 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OcugenMay 3, 2024 | finance.yahoo.comOcugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comOcugen Announces CSO to Present on Modifier Gene Therapy at Retina World CongressMay 1, 2024 | prnewswire.comIMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmApril 30, 2024 | benzinga.comLatest News for Ocugen Stock (NASDAQ:OCGN)April 30, 2024 | markets.businessinsider.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OcugenApril 29, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of InvestorsApril 29, 2024 | markets.businessinsider.comOcugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024April 29, 2024 | fool.comCan Ocugen Stock Keep Churning Higher?April 29, 2024 | globenewswire.comOcugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024April 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGNApril 26, 2024 | prnewswire.comROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGNApril 26, 2024 | finance.yahoo.comOcugen (OCGN) to Report Q1 Earnings: What's in the Cards?April 26, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OcugenApril 26, 2024 | globenewswire.comUPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual MeetingApril 26, 2024 | globenewswire.comOcugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual MeetingApril 23, 2024 | prnewswire.comIMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmApril 22, 2024 | marketbeat.comOcugen (NASDAQ:OCGN) Given New $5.00 Price Target at Chardan CapitalChardan Capital raised their price objective on Ocugen from $4.00 to $5.00 and gave the stock a "buy" rating in a research note on Monday.April 22, 2024 | markets.businessinsider.comKey Takeaways From Ocugen Analyst RatingsApril 21, 2024 | markets.businessinsider.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OcugenApril 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Bible Shocker: Have You Seen Elon Musk’s Miracle? (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process. Click here for the full story… OCGN Media Mentions By Week OCGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCGN News Sentiment▼0.440.42▲Average Medical News Sentiment OCGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCGN Articles This Week▼243▲OCGN Articles Average Week Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Tourmaline Bio News Solid Biosciences News TScan Therapeutics News Replimune Group News Black Diamond Therapeutics News Alvotech News Aura Biosciences News Fate Therapeutics News Lexeo Therapeutics News iTeos Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCGN) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressMan who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the Markets[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
